Ignite Creation Date:
2025-12-24 @ 3:38 PM
Ignite Modification Date:
2025-12-26 @ 2:37 AM
Study NCT ID:
NCT05267392
Status:
UNKNOWN
Last Update Posted:
2022-03-04
First Post:
2021-12-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy
Sponsor:
Instituto Portugues de Oncologia, Francisco Gentil, Porto
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-02-16
Start Date Type:
ACTUAL
Primary Completion Date:
2023-07
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-01
Completion Date Type:
ESTIMATED
First Submit Date:
2021-12-13
First Submit QC Date:
None
Study First Post Date:
2022-03-04
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-02-23
Last Update Post Date:
2022-03-04
Last Update Post Date Type:
ACTUAL